RICHMOND, VA--(Marketwired - July 15, 2014) - ALR Technologies (OTCQB: ALRT) a medical device company providing remote monitoring and care facilitation for patients with chronic diseases, announces today that online consultations for its new Insulin Dose Adjustment Consultation System (IDAC) will be provided by the endocrinology practice of Dr. Mayer B. Davidson, one of the world's leading experts on diabetes and insulin.
ALRT had announced the details of its new IDAC system in a news release on May 7, 2014.
Dr. Davidson's endocrinology practice will provide the dosing opinion based on review of actual blood glucose data, provided electronically by ALRT's Health-e-Connect System, along with other key data that is necessary for prescribing, such as current insulin dosage, gender, height and weight.
The IDAC system is designed to assist Primary Care Physicians (PCPs) in maintaining patients at an optimal insulin dose, stabilizing A1c levels and potentially reducing complications and related costs of treatment. In addition, a readily available endocrinology consult may reduce the reluctance of some PCPs to prescribe insulin even when the treatment guidelines would indicate a patient requires insulin. Finally, the remote monitoring feature of ALRT's Health-e-Connect system may lessen the very real problem of insulin non-adherence and non-persistence by many patients. ALRT's Diabetes Care Facilitators (DCFs) will be trained on physician-approved protocols to recognize non-adherence in the patient blood glucose trends so the DCFs can then arrange a care intervention without waiting for the next physician visit by the patient.
"We think that many primary care physicians will welcome a near-effortless consultation on their insulin doses from such a respected expert in diabetes," commented Sidney Chan, Chief Executive Officer of ALR Technologies. "We are honored to partner with Dr. Davidson who will be an invaluable resource to these physicians."
Dr. Mayer B. Davidson added: "The reality is that many physicians do not have the time to regularly adjust the patient's dose to achieve optimal glucose control, while other physicians are concerned about writing an insulin prescription because of the potential adverse events that could flow from an improper dose. ALRT's technology will allow me to assist many physicians with these challenges and to bring intensive blood glucose control to many more patients. This is a win for patients and a win for the healthcare system through more intensive management of diabetes."
A video explaining the new platform can be found here: http://youtu.be/rRxEKUE4tkA
About Dr. Mayer B. Davidson
Dr. Davidson has published numerous academic studies on insulin and insulin resistance, including a recent study in the American Journal of Managed Care in which a group of patients with diabetes saw their A1C levels drop from 11.1% to 7.2% through more careful, and more regular, management of their medication. (See: American Journal of Managed Care Volume 16, pages 652-656, 2010) Dr. Davidson is Professor of Medicine at both the David Geffen School of Medicine at UCLA and Charles R. Drew University. Dr. Davidson was President of the American Diabetes Association in 1997-1998. A renowned researcher and speaker on type 2 diabetes and insulin resistance, Dr. Davidson has presented hundreds of lectures nationally and internationally. He has served on the Editorial Boards of Diabetes Care, Diabetes Spectrum, Clinical Diabetes, Diabetes Reports, Today in Medicine, Geriatrics and the Journal of Clinical Endocrinology and Metabolism and was a Consulting Editor of Hippocrates and an Associate Editor of Endo Trends. He currently serves on the Editorial Board of Diabetes Research & Clinical Practice. Further, Dr. Davidson was the Founding Editor of Current Diabetes Reports and was the Editor-in-Chief of Diabetes Care from 2002 through 2006, the leading clinical journal for the diabetes community. Dr. Davidson's contributions to the medical literature include 3 books on diabetes care, 168 scientific papers, 31 book chapters, 59 reviews and 54 editorials and invited articles.
About ALR Technologies Inc.
ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with chronic diseases. ALRT has developed the FDA-cleared and HIPAA compliant Health-e-Connect System that collects data from blood glucose meters and uploads to a secure website. Trained Facilitators use the System to effect efficiency of care among patients, clinicians and caregivers to improve outcomes and assist health plans to optimize their quality goals. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data. More information about ALR Technologies, Inc. can be found at www.alrt.com.
ALR Technologies is active in providing articles, videos and information on diabetes via social media. ALR Technologies can be found on Facebook at: https://www.facebook.com/ALRTechnologies and on Twitter at: https://twitter.com/ALRTechnologies.
This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words "estimate", "expect", "anticipate", "believe" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company's quarterly filings with the Securities Exchange.